Substance Use Disorder-Related Deaths and Maternal Mortality in New Mexico, 2015-2019

被引:1
|
作者
Fuchs, Jessica R. [1 ]
Schiff, Melissa A. [2 ]
Coronado, Eirian [1 ]
机构
[1] New Mexico Dept Hlth, 2040 S Pacheco St, Santa Fe, NM 87505 USA
[2] Univ New Mexico, Dept Internal Med, Sch Med, 1 Univ New Mexico, Albuquerque, NM 87131 USA
关键词
Maternal mortality; Substance use; Mental health; Pregnancy; Postpartum; RELAPSE; WOMEN;
D O I
10.1007/s10995-023-03691-8
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundIn recent decades, maternal mortality has increased across the U.S. Experiences of pregnant and postpartum people with Substance Use Disorder (SUD)-related deaths have not been previously evaluated in New Mexico. The aim of this study was to analyze risk factors related to substance use and explore substance use patterns among pregnancy-associated deaths in New Mexico from 2015 to 2019.MethodsWe conducted an analysis of pregnancy-associated deaths to assess the association between demographics, pregnancy factors, circumstances surrounding death, treatment of mental health conditions, and experiences with social stressors among Substance Use Disorder (SUD)-related and non-SUD-related deaths. We performed univariate analyses of risk factors using chi-square tests to assess the differences between SUD-related and non-SUD-related deaths. We also examined substance use at time of death.ResultsPeople with SUD-related deaths were more likely to die 43-365 days postpartum (81% vs. 45%, p-value = 0.002), have had a primary cause of death of mental health conditions (47% vs 10%, p < 0.001), have died of an overdose (41% vs. 8%, p-value = 0.002), have had experienced any social stressors (86% vs 30%, p < 0.001) compared to people with non-SUD-related deaths, and received treatment for SUD at any point before, during, or after pregnancy (49% vs. 2%, p < 0.001). The substances most used at time of death were amphetamines (70%), and most cases engaged in polysubstance use (63%).Conclusions for PracticeProviders, health departments, and community organizations must prioritize supporting people using substances during and after pregnancy to prevent death and improve quality of life for pregnant and postpartum people. SignificanceWhat is Already Known on this Subject? Maternal mortality rates have been increasing across the U.S. Substance use and overdoses are leading causes of death among pregnant and postpartum people. Return to use in the postpartum period following abstinence during pregnancy is common. New Mexico has some of the highest rates of death attributed to alcohol use, and experiences high rates of substance use.What does this study add? This study provides background on risk factors for Substance Use Disorder (SUD)-related death among pregnant and postpartum people in New Mexico. It explores experiences with mental health treatments and social stressors, and substance use patterns among pregnant and postpartum people with SUD-related deaths.
引用
收藏
页码:23 / 33
页数:11
相关论文
共 47 条
  • [21] Excessive alcohol use and drug overdose deaths, New Mexico, 2015-2016
    Mahdi, Ihsan
    Tomedi, Laura E.
    Gerrard, Chandra Y.
    Lathrop, Sarah
    Landen, Michael
    DRUG AND ALCOHOL DEPENDENCE, 2020, 215
  • [22] DEMOGRAPHIC DISPARITIES IN THE CASCADE OF CARE FOR ALCOHOL USE DISORDER: ANALYSIS OF 2015-2019 NATIONAL SURVEY ON DRUG USE AND HEALTH DATA
    Mintz, C. M.
    Knox, J.
    Hasin, D. S.
    Martins, S. S.
    Kranzler, H. R.
    Greene, E.
    Grucza, R. A.
    Bierut, L. J.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 46 : 174A - 174A
  • [23] High Risk of Substance Use Disorder-Related Outcomes in Veterans Released from Correctional Facilities in Mid to Late Life
    Barry, Lisa C.
    Steffens, David C.
    Covinsky, Kenneth E.
    Conwell, Yeates
    Boscardin, John
    Li, Yixia
    Byers, Amy L.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2023, 38 (05) : 1109 - 1118
  • [24] Assessment of Nutrition Education in Substance Use Disorder Treatment Facilities in New Mexico
    Kennedy, Natalie
    Gonzales-Pacheco, Diana
    Cerami, Jean
    Coakley, Kathryn E.
    ALCOHOLISM TREATMENT QUARTERLY, 2025, 43 (01) : 97 - 106
  • [25] Evaluation of Trends in Alcohol Use Disorder-Related Mortality in the US Before and During the COVID-19 Pandemic
    Yeo, Yee Hui
    He, Xinyuan
    Ting, Peng-Sheng
    Zu, Jian
    Almario, Christopher V.
    Spiegel, Brennan M. R.
    Ji, Fanpu
    JAMA NETWORK OPEN, 2022, 5 (05)
  • [26] Sociodemographic factors of violent deaths related to licit or ilicit psychoactive substances: a cross-sectional study, Ceará, Brazil, 2015-2019
    de Holanda Junior, Wanderley Pinheiro
    Maceno, Raimunda Hermelinda Maia
    Ferreira, Maria Augusta Drago
    EPIDEMIOLOGIA E SERVICOS DE SAUDE, 2024, 33
  • [27] Exploring racial and secondary substance use differences in route of administration of opioid drugs: Analysis of the 2015-2019 treatment admission data
    Gilbert, Lauren R.
    Tawiah, Nii A.
    Adepoju, Omolola E.
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 162
  • [28] Substance Use and Misuse among Adults with Chronic Obstructive Pulmonary Disease in the United States, 2015-2019: Prevalence, Association, and Moderation
    Alanazi, Abdullah M. M.
    Alqahtani, Mohammed M.
    Alquaimi, Maher M.
    Alotaibi, Tareq F.
    Algarni, Saleh S.
    Ismaeil, Taha T.
    Alanazi, Ahmad A.
    Alasmari, Moudi M.
    Alhuthail, Eyas A.
    Alasmari, Ali M.
    Gibson-Young, Linda
    Jayawardene, Wasantha P.
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (01)
  • [29] Prevalence and Sociodemographic Characteristics of People with Prescription Stimulant Use Disorder: Results From the National Survey on Drug Use and Health, 2015-2019
    Smith, Noah I.
    Moga, Daniela C.
    Delcher, Chris
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 441 - 441
  • [30] Animal use and opportunities for reduction in carcinogenicity studies supporting approved new drug applications in the US, 2015-2019
    Manuppello, Joseph
    Slankster-Schmierer, Eryn
    Baker, Elizabeth
    Sullivan, Kristie
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2023, 137